Advanced Urothelial CarcinomaPhase 1MACOCUC-01NCT05738161
Magrolimab in Combination With Cytotoxic Chemotherapy in Advanced Urothelial Carcinoma
A Phase 1 study testing Magrolimab, Cisplatin and Gemcitabine in people with Advanced Urothelial Carcinoma, run by Insel Gruppe AG, University Hospital Bern.
Trial summary
In their "Magrolimab" research project, the investigators want to find out whether the new drug Magrolimab in combination with conventional chemotherapy is well tolerated and whether survival or progression-free survival improves. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Advanced Urothelial Carcinoma
- What is being tested?
- Magrolimab, Cisplatin and Gemcitabine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 0 participants
- Where
- No sites listed yet
- Study dates
- 21 Jun 2023to 27 Feb 2024
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Written informed consent before trial treatment and prior to any trial specific procedures.
- Male or female age ≥ 18 years.
- Histologically confirmed locally advanced or metastatic predominant urothelial carcinoma of the bladder or the upper urinary tract being considered not suitable for curative multimodality treatment including surgery by a multidisciplinary tumor board. All histological subtypes eligible if urothelial carcinoma predominant (exception: Small cell component).
- ECOG performance status 0-2 within 7 days prior to IMP treatment start.
- Bone marrow function (within 14 days prior to IMP treatment start): Hemoglobin ≥ 100 g/L, absolute neutrophil count ≥ 1.5 x 109/L, platelet count ≥ 100 x 109/L.
- Hepatic function (within 14 days prior to IMP treatment start): Bilirubin ≤ 1.5 x ULN (except for patients with documented history of Gilbert's disease or genetic equivalent ≤ 3.0 x ULN and primarily unconjugated), AST ≤ 2.5 x ULN, ALT ≤ 2.5 x ULN, alkaline phosphatase ≤ 2.5 x ULN.
Show all 16Show fewer
- Renal function (within 14 days prior to IMP treatment start): eGFR > 60 mL/min/1.73m., according to CKD-EPI formula.
- Cardiac function (within 28 days prior to IMP treatment start): Left Ventricular Ejection Fraction (LVEF) ≥ 50% as determined by echocardiography (ECHO).
- Women with child-bearing potential are using effective contraception, are not pregnant or lactating and agree not to become pregnant during trial treatment and 6 months after the last dose of IMP. A negative pregnancy test within 7 days prior to IMP treatment start is required for all women with child-bearing potential.
- Men agree not to father a child during trial treatment and 6 months after the last dose of study drug.
- Measurable disease by CT or MRI as per RECIST 1.1 criteria. Tumor lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
- Male and female patients of childbearing potential who engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception.
- Life expectancy at least 12months.
- Willing and able to comply with the requirements and restrictions in this protocol.
- Pre-treatment blood cross-match completed.
- Body weight > 30kg
Who cannot join
- Any pathological evidence of small-cell carcinoma component.
- History of hematologic or primary solid tumor malignancy, unless in remission for at least 3 years prior to IMP treatment start, with the exception of adequately treated cervical carcinoma in situ, localized non-melanoma skin cancer or low risk localized prostate cancer (T1-T2a, Gleason <7, PSA <10 ng/ml).
- Concurrent treatment with Prednisone (or equivalent); except for the prophylactic medication before chemotherapy, treatment of acute hypersensitivity reactions, or chronic treatment (initiated > 6 months prior to IMP treatment start) at low dose (≤ 10 mg/day of Prednisone or an equivalent corticosteroid).
- Previous treatment with a PD-1, PD-L1, or CTLA4 inhibitor.
- Previous chemotherapy with Cisplatin and Gemcitabine.
- Treatment with an anticancer biologic agent within 4 weeks prior to IMP treatment start or have had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to IMP treatment start.
Show all 37Show fewer
- (NOTE: Localized non-CNS radiotherapy, previous hormonal therapy with luteinizing hormone releasing hormone [LHRH] agonists for prostate or breast cancer, and treatment with bisphosphonates and Receptor Activator of Nuclear factor KappaB Ligand (RANKL) inhibitors are not criteria for exclusion. There is no required minimum washout period for these therapies. Patients should be recovered from the effects of radiation.)
- Use of other investigational drugs (drugs not marketed for any indication) within 28 days or 5 half-lives (whichever is longer) of IMP treatment start.
- Current participation in another interventional clinical trial. Patients participating in observational studies are eligible.
- Have known active Central Nervous System (CNS) metastases and / or carcinomatous meningitis. Patients with previously treated brain metastases may participate provided they have stable CNS disease for at least 4 weeks prior to enrollment and all neurologic symptoms have returned to baseline, have no evidence of new or enlarging brain metastases, and are taking ≤ 10 mg/day of Prednisone or its equivalent. All patients with carcinomatous meningitis are excluded regardless of clinical stability. Current or prior use of immunosuppressive medication within 28 days prior to IMP treatment start, with the exception of intranasal and inhaled corticosteroids or systemic corticosteroids as mentioned above.
- Major surgical procedure within 28 days prior to IMP treatment start.
- Have ongoing AEs not recovered to grade 1 or better due to a previously administered agent.
- (Note: If patients received major surgery, they must have recovered adequately from the toxicity and / or complications from the intervention prior to starting therapy.)
- Preexisting peripheral sensory neuropathy (> grade 1).
- Uncontrolled diabetes mellitus.
- Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this criterion:
- Patients with vitiligo or alopecia
- Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement
- Any chronic skin condition that does not require systemic therapy
- Patients without active disease in the last 5 years prior to IMP treatment start may be included but only after consultation with the sponsor
- Patients with celiac disease controlled by diet alone
- Patients with an HIV detectable viral load at known history of HIV-1 or 2.
- Have active Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV). In patients with a history of HBV or HCV, patients with detectable viral loads will be excluded.
- Patients who test positive for hepatitis B surface antigen (HBsAg). Patients who test positive for hepatitis B core antibody (anti-HBc) will require HBV DNA by quantitative polymerase chain reaction (PCR) for confirmation of active disease.
- Patients who test positive for HCV antibody. Patients who test positive for HCV antibody will require HCV RNA by quantitative PCR for confirmation of active disease. Patients with a known history of HCV or a positive HCV antibody test will not require a HCV antibody at screening and will only require HCV RNA by quantitative PCR for confirmation of active disease.
- History of allogeneic organ transplant.
- Receipt of live attenuated vaccine (active influenza vaccines excluded) within 30 days prior to IMP treatment start. Note: Patients, if enrolled, should not receive live vaccine during trial treatment and up to 30 days after the last IMP dose.
- Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness / social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent.
- Met any of the following criteria for cardiac disease:
- Myocardial infarction or unstable angina pectoris within 6 months of IMP treatment start.
- History of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation), high-grade atrioventricular block, or other cardiac arrhythmias requiring antiarrhythmic medications (except for atrial fibrillation that is well controlled with antiarrhythmic medication); history of QT interval prolongation.
- New York Heart Association (NYHA) class III or greater congestive heart failure or LVEF of < 40%.
- Have active serious infection requiring antibiotics.
- Any medical condition that, in the investigator's or sponsor's opinion, poses an undue risk to the patient's participation in the study.
- Any concurrent drug contraindicated for blocking the effect of Magrolimab; this includes systemic corticosteroids (exceptions see above), Methotrexate, Azathioprine, and Tumor Necrosis Factor (TNF)-α blockers.
- Any concurrent drug contraindicated for use with Cisplatin or Gemcitabine according to the locally approved product information.
- Known hypersensitivity to Magrolimab, Cisplatin, or Gemcitabine, its metabolites, or formulation excipients.
About this study
Official title: A Phase 1, Single Arm Investigator-initiated Study to Investigate the Safety of Combining the Antibody Magrolimab With Standard First Line Platinum-based Chemotherapy (With Cisplatin / Gemcitabine) in Advanced Urothelial Carcinoma
In their "Magrolimab" research project, the investigators want to find out whether the new drug Magrolimab in combination with conventional chemotherapy is well tolerated and whether survival or progression-free survival improves.
Read the detailed description
About 10% of the patients with urothelial carcinoma of the bladder present with advanced disease at time of diagnosis. The five-year overall survival is poor (13%) as treatment options are limited to platinum-based chemotherapy and immune checkpoint inhibitors. Therefore, new therapeutic approaches are urgently needed.
Stimulation of the innate immune response to cancer cells using macrophages to attack tumor cells represents a novel approach of cancer immunotherapy. One mechanism used by tumor cells to prevent phagocytosis and thus avoid clearance by the immune system is to up regulate "don't eat me" signals such as CD47. Blockade of CD47 represents a novel immunotherapy allowing the immune system to eliminate cancer cells. Cytotoxic chemotherapy, in particular Gemcitabine, is known to upregulate calreticulin which is a so called "eat me" signal. Consequently, a combination of Gemcitabine with an anit-CD47 antibody could potentiate the tumor-cell killing effects.
Magrolimab is a first-in-class fully humanized monoclonal antibody blocking CD47 and currently investigated as an immunotherapy in solid as well as hematologic malignancies in several phase 1 - 3 clinical trials. Furthermore, Magrolimab as a novel myeloid specific immune checkpoint inhibitor could be the urgently needed new therapeutic weapon for bladder cancer treatment if it proves to add a significant therapeutic benefit to conventional chemotherapy in advanced muscle invasive bladder cancer. The expected benefit of combining chemotherapy with Magrolimab might be manifold:
- It could result in durable systemic anti-cancer responses and subsequently increase disease free and overall survival
- It could increase the response rate and prolong survival in the metastatic setting
- In case of positive results of this trial, the investigators could expand this approach to the peri-operative setting:
- In the neoadjuvant setting, it could increase the rate of pathologic complete remission (pCR, ypT0) and subsequently reduce the risk of local recurrence and bladder cancer related death
- In the adjuvant setting, it could induce antitumor immune response in micro metastases and subsequently reduce risk of local recurrence and improve cancer specific survival.
The primary endpoint of the trial is incidence of adverse events (AEs) and laboratory abnormalities according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0 Secondary endpoints are
- PFS from date of dose initiation as determined by investigator assessment per RECIST, Version 1.1
- DOR, defined as time from first documentation of complete response or partial response to the earliest date of documented disease progression, per RECIST, Version 1.1, or death from any cause, whichever occurs first, as determined by investigator assessment
- OS, defined as date of dose initiation to death from any cause.
- Conditions
- Advanced Urothelial Carcinoma
- Being tested
- Magrolimab, Cisplatin, Gemcitabine
- Keywords
- Chemotherapy, Antibody Drug Therapy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MagrolimabDrug
Also called Hu-5F9-G4
Magrolimab in combination with cytotoxic chemotherapy in advanced urothelial carcinoma
CisplatinDrug
Also called L01XA01 Cisplatin
Standard first line platinum-based chemotherapy in advanced urothelial carcinoma
GemcitabineDrug
Also called L01BC05 Gemcitabine
Standard first line platinum-based chemotherapy in advanced urothelial carcinoma
| Study group | Role | What they receive |
|---|---|---|
| Magrolimab in combination with Cisplatin and Gemcitabine | Experimental | Magrolimab therapy in combination with standard first line platinum-based chemotherapy (with Cisplatin / Gemcitabine) in advanced urothelial carcinoma. Receives: Drug: Magrolimab; Drug: Cisplatin; Drug: Gemcitabine |
What is being measured
The primary outcome is the main question the study is designed to answer.
Dose Limiting Toxicity in Run-in Phase
Incidence of DLTs in participants of the safety run-in phase
Measured: End of cycle 1 (day 21)
Proportion of participants with any AEs of severity grade 3 or higher
Proportion of participants with any AEs of severity grade 3 or higher according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 over 6 months after IMP dose initiation
Measured: Up to 6 months after IMP dose initiation
Secondary outcomes (4)
Progression-Free Survival
PFS from date of dose initiation as determined by investigator assessment per RECIST, Version 1.1
Measured: 48 months
Duration Of Response
DOR, defined as time from first documentation of complete response or partial response to the earliest date of documented disease progression, per RECIST, Version 1.1, or death from any cause, whichever occurs first, as determined by investigator assessment
Measured: 48 months
Date of dose initiation to death
DOS, defined as date of dose initiation to death from any cause.
Measured: 48 months
Proportion of complete or partial response (ORR)
The proportion of patients who achieve a complete response or partial response (ORR), as measured by response evaluation criteria in solid tumors (RECIST version 1.1, as determined by investigator assessment
Measured: 48 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Feb 2023
- Study start21 Jun 2023
- Primary completion27 Feb 2024
- Study completion27 Feb 2024
Why it stopped: IMP security Issues reported by Sponsor
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Advanced Urothelial CarcinomaStudies of the same condition, open and under way.
- More trials run by Insel Gruppe AG, University Hospital BernThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Prospective investigator-initiated single-arm, phase 1 clinical trial, risk category C
- Masking
- None (open label)
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- Insel Gruppe AG, University Hospital Bern
- Sponsor type
- University, hospital or other
- Collaborators
- University of Bern, Swiss National Science Foundation
- Responsible party
- Sponsor
- Investigators
- Bernhard Kiss, Professor, Principal investigator, Universtary Hospital Insel Bern
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05738161
- Sponsor's protocol ID
- CO-SW-548-6347
- Other IDs
- 2023-00258, 2023
- Acronym
- MACOCUC-01
- Status last verified
- Jul 2024
- First submitted
- 9 Feb 2023
- Last updated
- 5 Jul 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Jul 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 1, Single Arm Investigator-initiated Study to Investigate the Safety of Combining the Antibody Magrolimab With Standard First Line Platinum-based Chemotherapy (With Cisplatin / Gemcitabine) in Advanced Urothelial Carcinoma
- ClinicalTrials.gov ID
- NCT05738161
- Acronym / sponsor ID
- MACOCUC-01 / CO-SW-548-6347
- Conditions
- Advanced Urothelial Carcinoma
- Keywords
- Chemotherapy, Antibody Drug Therapy
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- WithdrawnReason stopped: IMP security Issues reported by Sponsor
- Enrolment
- 0 participants (actual)
- Lead sponsor
- Insel Gruppe AG, University Hospital BernUniversity, hospital or other
- Collaborators
- University of Bern, Swiss National Science Foundation
- Study start
- 21 Jun 2023 (actual)
- Primary completion
- 27 Feb 2024 (actual)
- Study completion
- 27 Feb 2024 (actual)
- First posted
- 21 Feb 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In their "Magrolimab" research project, the investigators want to find out whether the new drug Magrolimab in combination with conventional chemotherapy is well tolerated and whether survival or progression-free survival improves.
Detailed description
About 10% of the patients with urothelial carcinoma of the bladder present with advanced disease at time of diagnosis. The five-year overall survival is poor (13%) as treatment options are limited to platinum-based chemotherapy and immune checkpoint inhibitors. Therefore, new therapeutic approaches are urgently needed.
Stimulation of the innate immune response to cancer cells using macrophages to attack tumor cells represents a novel approach of cancer immunotherapy. One mechanism used by tumor cells to prevent phagocytosis and thus avoid clearance by the immune system is to up regulate "don't eat me" signals such as CD47. Blockade of CD47 represents a novel immunotherapy allowing the immune system to eliminate cancer cells. Cytotoxic chemotherapy, in particular Gemcitabine, is known to upregulate calreticulin which is a so called "eat me" signal. Consequently, a combination of Gemcitabine with an anit-CD47 antibody could potentiate the tumor-cell killing effects.
Magrolimab is a first-in-class fully humanized monoclonal antibody blocking CD47 and currently investigated as an immunotherapy in solid as well as hematologic malignancies in several phase 1 - 3 clinical trials. Furthermore, Magrolimab as a novel myeloid specific immune checkpoint inhibitor could be the urgently needed new therapeutic weapon for bladder cancer treatment if it proves to add a significant therapeutic benefit to conventional chemotherapy in advanced muscle invasive bladder cancer. The expected benefit of combining chemotherapy with Magrolimab might be manifold:
- It could result in durable systemic anti-cancer responses and subsequently increase disease free and overall survival
- It could increase the response rate and prolong survival in the metastatic setting
- In case of positive results of this trial, the investigators could expand this approach to the peri-operative setting:
- In the neoadjuvant setting, it could increase the rate of pathologic complete remission (pCR, ypT0) and subsequently reduce the risk of local recurrence and bladder cancer related death
- In the adjuvant setting, it could induce antitumor immune response in micro metastases and subsequently reduce risk of local recurrence and improve cancer specific survival.
The primary endpoint of the trial is incidence of adverse events (AEs) and laboratory abnormalities according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0 Secondary endpoints are
- PFS from date of dose initiation as determined by investigator assessment per RECIST, Version 1.1
- DOR, defined as time from first documentation of complete response or partial response to the earliest date of documented disease progression, per RECIST, Version 1.1, or death from any cause, whichever occurs first, as determined by investigator assessment
- OS, defined as date of dose initiation to death from any cause.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Prospective investigator-initiated single-arm, phase 1 clinical trial, risk category C
| Arm | Type | Receives |
|---|---|---|
| Magrolimab in combination with Cisplatin and Gemcitabine | Experimental | Drug: Magrolimab, Drug: Cisplatin, Drug: GemcitabineMagrolimab therapy in combination with standard first line platinum-based chemotherapy (with Cisplatin / Gemcitabine) in advanced urothelial carcinoma. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (16 listed)
- Written informed consent before trial treatment and prior to any trial specific procedures.
- Male or female age ≥ 18 years.
- Histologically confirmed locally advanced or metastatic predominant urothelial carcinoma of the bladder or the upper urinary tract being considered not suitable for curative multimodality treatment including surgery by a multidisciplinary tumor board. All histological subtypes eligible if urothelial carcinoma predominant (exception: Small cell component).
- ECOG performance status 0-2 within 7 days prior to IMP treatment start.
- Bone marrow function (within 14 days prior to IMP treatment start): Hemoglobin ≥ 100 g/L, absolute neutrophil count ≥ 1.5 x 109/L, platelet count ≥ 100 x 109/L.
Key exclusion criteria (37 listed)
- Any pathological evidence of small-cell carcinoma component.
- History of hematologic or primary solid tumor malignancy, unless in remission for at least 3 years prior to IMP treatment start, with the exception of adequately treated cervical carcinoma in situ, localized non-melanoma skin cancer or low risk localized prostate cancer (T1-T2a, Gleason <7, PSA <10 ng/ml).
- Concurrent treatment with Prednisone (or equivalent); except for the prophylactic medication before chemotherapy, treatment of acute hypersensitivity reactions, or chronic treatment (initiated > 6 months prior to IMP treatment start) at low dose (≤ 10 mg/day of Prednisone or an equivalent corticosteroid).
- Previous treatment with a PD-1, PD-L1, or CTLA4 inhibitor.
- Previous chemotherapy with Cisplatin and Gemcitabine.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MagrolimabAlso: Hu-5F9-G4Magrolimab in combination with cytotoxic chemotherapy in advanced urothelial carcinoma | Drug | Magrolimab in combination with Cisplatin and Gemcitabine |
| CisplatinAlso: L01XA01 CisplatinStandard first line platinum-based chemotherapy in advanced urothelial carcinoma | Drug | Magrolimab in combination with Cisplatin and Gemcitabine |
| GemcitabineAlso: L01BC05 GemcitabineStandard first line platinum-based chemotherapy in advanced urothelial carcinoma | Drug | Magrolimab in combination with Cisplatin and Gemcitabine |
Primary outcome
Dose Limiting Toxicity in Run-in Phase
Time frame: End of cycle 1 (day 21)
Incidence of DLTs in participants of the safety run-in phase
Proportion of participants with any AEs of severity grade 3 or higher
Time frame: Up to 6 months after IMP dose initiation
Proportion of participants with any AEs of severity grade 3 or higher according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 over 6 months after IMP dose initiation
4 secondary outcomes
Progression-Free Survival
Time frame: 48 months
Duration Of Response
Time frame: 48 months
Date of dose initiation to death
Time frame: 48 months
Proportion of complete or partial response (ORR)
Time frame: 48 months
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Jul 2024.
- Individual participant dataSharing planned: No
Related trials for Advanced Urothelial Carcinoma
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingPhase 1
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Advanced/Metastatic Solid Tumors, Bladder Cancer
RecruitingPhase 3
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma
RecruitingPhase 1
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Urinary Bladder Neoplasms, Neoplasm Metastasis
RecruitingPhase 1
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Metastatic Solid Tumor, Recurrent Solid Tumor
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Bernhard Kiss, Professor principal investigator
Universtary Hospital Insel Bern
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Magrolimab, Cisplatin and Gemcitabine in people with Advanced Urothelial Carcinoma, run by Insel Gruppe AG, University Hospital Bern.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 16 inclusion and 37 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 5 Jul 2024. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Dose Limiting Toxicity in Run-in Phase (time frame: End of cycle 1 (day 21)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Jul 2024.